Cargando…

Real-World Outcomes With Generic Pomalidomide in Relapsed Refractory Multiple Myeloma—Experience From a Tertiary Care Cancer Center

PURPOSE: The prognosis of relapsed and refractory multiple myeloma (RRMM) that is refractory to bortezomib and lenalidomide is very poor wherein the median survival is between 3 and 9 months. We did this retrospective analysis to study the pattern of utilization, tolerance, and outcomes with pomalid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bondili, Suresh Kumar, Bagal, Bhausaheb, Zawar, Abhinav, Ventrapati, Pradeep, Thorat, Jayashree, Gokarn, Anant, Punatar, Sachin, Nayak, Lingaraj, Bonda, Avinash, Jain, Hashmukh, Sengar, Manju, Khattry, Navin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2021
Materias:	ORIGINAL REPORTS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8081531/ https://www.ncbi.nlm.nih.gov/pubmed/33689483 http://dx.doi.org/10.1200/GO.20.00228

Ejemplares similares

Role of cytogenetic abnormalities detected by fluorescence in situ hybridization as a prognostic marker: Pathogenesis & clinical course in patients with B-chronic lymphocytic leukaemia
por: Shetty, Dhanlaxmi, et al.
Publicado: (2021)

A Limited Sampling Strategy for Therapeutic Drug Monitoring of Mycophenolate Mofetil for Prophylaxis of Acute Graft-Versus-Host Disease in Allogeneic Stem Cell Transplantation
por: Gota, Vikram, et al.
Publicado: (2020)

Role of Curcumin in Reducing Toxicities Associated With Mucosal Injury Following Melphalan-Based Conditioning in Autologous Transplant Setting
por: Punatar, Sachin, et al.
Publicado: (2022)

P454: ACUTE MYELOID LEUKEMIA (AML) WITH IDH1 AND IDH2 MUTATIONS CAN BE EFFECTIVELY RISK STRATIFIED BASED ON THE PRESENCE ADVERSE RISK GENOMIC FEATURES.
por: Bhide, Aniket, et al.
Publicado: (2023)

A Prospective Survey to Understand the Preferences and Perspectives of Patients with Hematological Malignancies in a Tertiary Cancer Care Setting in India (CANCOV SURVEY)
por: Sharma, Dr. Neha, et al.
Publicado: (2021)

P003: A retrospective study to evaluate the reliability of staging and risk stratification of adolescent and adult patients with Hodgkin’s lymphoma registered in the lymphoma clinic at Tata Memorial Centre.
por: Jain, Hasmukh, et al.
Publicado: (2022)

A novel pro-oxidant combination of resveratrol and copper reduces transplant related toxicities in patients receiving high dose melphalan for multiple myeloma (RESCU 001)
por: Agarwal, Anshul, et al.
Publicado: (2022)

Infection Prevalence in Adolescents and Adults With Acute Myeloid Leukemia Treated in an Indian Tertiary Care Center
por: Jain, Hasmukh, et al.
Publicado: (2020)

NARASIMHA: Novel Assay based on Targeted RNA Sequencing to Identify ChiMeric Gene Fusions in Hematological Malignancies
por: Patkar, Nikhil, et al.
Publicado: (2020)

A novel machine-learning-derived genetic score correlates with measurable residual disease and is highly predictive of outcome in acute myeloid leukemia with mutated NPM1
por: Patkar, Nikhil, et al.
Publicado: (2019)

COVID‐19 in cancer patients on active systemic therapy – Outcomes from LMIC scenario with an emphasis on need for active treatment
por: Ramaswamy, Anant, et al.
Publicado: (2020)

Utility of Immunophenotypic Measurable Residual Disease in Adult Acute Myeloid Leukemia—Real-World Context
por: Patkar, Nikhil, et al.
Publicado: (2019)

Machine learning derived genomics driven prognostication for acute myeloid leukemia with RUNX1-RUNX1T1
por: Shaikh, Anam Fatima, et al.
Publicado: (2020)

Splenic marginal zone lymphoma relapsing as miliary lung mottling: an unusual presentation
por: Mandal, Tanmoy, et al.
Publicado: (2018)

Is long term storage of cryopreserved stem cells for hematopoietic stem cell transplantation a worthwhile exercise in developing countries?
por: Devadas, Santhosh Kumar, et al.
Publicado: (2017)

Comparison of the efficacy and safety of Rituximab (Mabthera™) and its biosimilar (Reditux™) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: A retrospective analysis
por: Roy, Partha Sarathi, et al.
Publicado: (2013)

Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia
por: Patkar, Nikhil, et al.
Publicado: (2018)

Correction: Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia
por: Patkar, Nikhil, et al.
Publicado: (2019)

SARS-CoV2 Infection in Hematopoietic Stem Cell Transplant recipients: A Case Series from a Tertiary Cancer Centre in India
por: Rajendra, Akhil, et al.
Publicado: (2021)

Study of stem cell homing & self-renewal marker gene profile of ex vivo expanded human CD34(+) cells manipulated with a mixture of cytokines & stromal cell-derived factor 1
por: Kode, Jyoti, et al.
Publicado: (2017)

Sequential Treatment of Arsenic Trioxide Followed by All Trans Retinoic Acid with Anthracyclines has Excellent Long-Term Cure in Acute Promyelocytic Leukemia
por: Devadas, Santhosh Kumar, et al.
Publicado: (2020)

Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy
por: Tembhare, Prashant Ramesh, et al.
Publicado: (2020)

Acute Myeloid Leukemia during the COVID Pandemic: Impact and the Indian Experience
por: Philip, Chepsy C, et al.
Publicado: (2022)

P360: MEASURABLE/MINIMAL RESIDUAL DISEASE (MRD) STATUS IS THE MOST RELEVANT INDICATOR OF CLINICAL OUTCOME IN MIXED PHENOTYPIC ACUTE LEUKEMIAS (MPAL)
por: Tembhare, Prashant, et al.
Publicado: (2023)

EMERALD: Emergency visit audit of patients treated under medical oncology in a tertiary cancer center: Logical steps to decrease the burden
por: Joshi, Amit, et al.
Publicado: (2017)

Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML)
por: Patkar, Nikhil, et al.
Publicado: (2021)

Population Pharmacokinetics of Pomalidomide
por: Li, Yan, et al.
Publicado: (2015)

Pomalidomide-induced hypothyroidism
por: Ali, Sulaiman Haji, et al.
Publicado: (2017)

Genomic Analysis of AZD1222 (ChAdOx1) Vaccine Breakthrough Infections in the City of Mumbai
por: Shetty, Arusha, et al.
Publicado: (2022)

Pomalidomide for the Treatment of Multiple Myeloma
por: Clark, Stephen M., et al.
Publicado: (2014)

Spotlight on pomalidomide: could less be more?
por: Zander, T, et al.
Publicado: (2017)

Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax
por: Gaur, Tarang, et al.
Publicado: (2023)

Profile of pomalidomide and its potential in the treatment of myelofibrosis
por: Gowin, Krisstina L, et al.
Publicado: (2015)

Pomalidomide Reduces Ischemic Brain Injury in Rodents
por: Tsai, Yan-Rou, et al.
Publicado: (2019)

Pomalidomide-Induced Pulmonary Toxicity in Multiple Myeloma
por: Modi, Dipenkumar, et al.
Publicado: (2015)

Current status of hematopoietic stem cell transplant in chronic myeloid leukemia
por: Gupta, Alok, et al.
Publicado: (2014)

New drugs in multiple myeloma – role of carfilzomib and pomalidomide
por: Jurczyszyn, Artur, et al.
Publicado: (2014)

Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma
por: Chanan-Khan, A A, et al.
Publicado: (2013)

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
por: Sivaraj, Dharshan, et al.
Publicado: (2018)

Pomalidomide-induced lung injury: A case report
por: Vivien, Alexandre, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9im54pcc4cbn70pds8nupjh19s